Atogepant

Unassigned

New Medicines

Episodic migraine - prophylaxis

Information

New molecular entity
Allergan
Allergan

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Calcitonin gene-related peptide (CGRP) receptor antagonist, orally-active small molecule
Numbers may be misleading, as many who experience migraine do not consult their GP, but migraine affects about 6% of men and 18% of women. In children it is more common in boys than in girls. The first attack is often in childhood and over 80% have had their first attack by the age of 30 [3].
Episodic migraine - prophylaxis
Oral